Corporate
Gossamer Bio Stock Crashes 78% as Seralutinib Narrowly Misses Phase 3 Endpoint, Still Eyes FDA Path
4d ago
You're signed outSign in or to get full access.
GB
Gossamer Bio (GOSS)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering Gossamer Bio.